Related Experiment Video
Updated: Aug 19, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
[The best of cardiac failure in 2004]
1Hôpital Ambroise Paré, Boulogne. guillaume.jondeau@apr.ap-hop-paris.fr
Insights
In 2004, medical device indications expanded for heart failure, including cardioversion and defibrillators. Advances were also made in diagnosing diastolic heart failure and utilizing new medications.
Area of Science:
- Cardiology
- Medical Devices
- Pharmacology
Context:
- 2004 saw significant advancements in heart failure management and treatment guidelines.
- Dissemination of indications for medical devices like cardioverters and defibrillators in heart failure.
- Emerging research in diastolic heart failure diagnosis and treatment.
Purpose:
- To review key developments in cardiac failure research and clinical practice from 2004.
- To highlight advancements in medical device applications for heart failure.
- To summarize progress in pharmacological and therapeutic interventions for heart failure.
Summary:
- Key 2004 developments include expanded indications for cardioversion and defibrillators (COMPANION, DEFINITE, SCD-HeFT, TOVA studies).
- Refined use of BNP for diagnosis and prognosis, emphasizing renal function and risks of therapy in non-study populations.
- Therapeutic advances in heart transplantation, circulatory assistance, diastolic heart failure diagnostics, and new medications (vasopressin antagonists, beta-blockers, cellular cardiomyoplasty).
Impact:
- The year marked a significant shift in understanding and managing heart failure, integrating new devices and therapies.
- Emphasis on early treatment initiation before hospital discharge, mirroring practices in coronary artery disease.
- Improved diagnostic and therapeutic strategies for diverse heart failure patient groups, including those with diastolic dysfunction.
Abstract:
Regarding cardiac failure, the year 2004 was notable for the dissemination of indications for the use of medical devices in heart failure: indications for cardioversion with the long awaited publication of the COMPANION study, advancement of the concept of intra-ventricular asynchronism, and studies of defibrillators in non-ischaemic cardiac failure (COMPANION, DEFINITE, SCD-HeFT, TOVA). Furthermore, pragmatic clinical studies allowed refinement of the uses of BNP (diagnostic and prognostic), underlining the importance of renal function and its progression during hospitalisation, and the risks of using strong, modern therapy in populations without "ad hoc" surveillance which do not correspond with study populations (aldactone in Canada). Just as in coronary patients, it appears to be important to commence full medical treatment prior to hospital discharge, because treatment is rarely changed thereafter. The management of seriously ill patients is evolving with several therapeutic advances: the methods of selecting patients for heart transplants have changed, with the advancement of opportunities for circulatory assistance. Attention has also been turned to the significant group, still poorly understood, of patients with diastolic heart failure, for whom diagnostic methods have been defined, as well as their clinical characteristics. Lastly the medication studies: new drugs in acute cardiac failure (preliminary results for vasopressin antagonists), wider indications for betablockers in elderly subjects (SENIORS), and advances in cellular cardiomyoplasty (using haemopoietic stem cells especially this year). It has been a fruitful year, difficult to summarise in a few lines, or even several pages....
More Related Videos
Related Concept Videos
Pathophysiology of Heart Failure
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure VI: Adjunct Therapies
Heart Failure VII: Nursing Interventions
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care

